Ikedieze Chukwu, MD
Internal Medicine · El Paso, TXNPI 1720285661
Payments from drug & device makers
Across 473 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AbbVie$1K
- Boehringer Ingelheim$534
- Abbott$461
- Astellas Pharma US Inc$370
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,70799%
- Education$1171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 105 | $1,607 |
| Lilly USA, LLC | 86 | $1,191 |
| AbbVie(2 entities) | 58 | $1,040 |
| Boehringer Ingelheim | 26 | $534 |
| Abbott | 22 | $461 |
| Astellas Pharma US Inc | 14 | $370 |
| Sanofi-aventis U.S. LLC | 23 | $341 |
| Pfizer | 22 | $319 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $286 |
| E.r. Squibb & Sons, L.L.C. | 17 | $270 |
| Amgen | 11 | $215 |
| AstraZeneca | 10 | $147 |
| Bayer | 6 | $132 |
| Upsher-smith Laboratories LLC | 8 | $123 |
| Johnson & Johnson | 8 | $118 |
| Phathom Pharmaceuticals, Inc. | 5 | $96 |
| Optinose US, Inc. | 5 | $76 |
| GSK | 4 | $70 |
| Merck | 4 | $64 |
| Dexcom, Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Corcept Therapeutics | 2 | $44 |
| Novartis | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| UCB, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Medtronic | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Exact Sciences | 1 | $14 |
How this compares
$7,824 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 698 | $945,297 |
| JanuviaSitagliptin Phosphate | 369 | $388,223 |
| JardianceEmpagliflozin | 333 | $366,046 |
| EliquisApixaban | 517 | $309,452 |
| TrulicityDulaglutide | 193 | $270,195 |
| RybelsusSemaglutide | 137 | $255,895 |
| MounjaroTirzepatide | 173 | $217,540 |
| MyrbetriqMirabegron | 152 | $106,377 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 99 | $93,641 |
| FarxigaDapagliflozin Propanediol | 101 | $92,764 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $85,190 |
| Xeljanz XrTofacitinib Citrate | 11 | $69,093 |
| LinzessLinaclotide | 75 | $67,379 |
| XareltoRivaroxaban | 63 | $65,209 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $58,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,607 | $1,201,193835 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,191 | $487,734366 claims |
| MerckJanuvia, Janumet Xr, Janumet | $64 | $466,165440 claims |
| Boehringer IngelheimJardiance, Tradjenta | $534 | $412,116386 claims |
| PfizerEliquis | $319 | $309,452517 claims |
| AstraZenecaFarxiga, Brilinta | $147 | $117,268128 claims |
| Astellas Pharma US IncMyrbetriq | $370 | $106,377152 claims |
| AbbVieLinzess, Creon | $1,040 | $89,67592 claims |
| GSKTrelegy Ellipta | $70 | $85,190107 claims |
| Johnson & JohnsonXarelto | $118 | $65,20963 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $341 | $55,11960 claims |
| NovartisEntresto | $31 | $44,58197 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in El Paso
- Javier VasalloEl Paso$2.5M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.